PDF herunterladen
CC BY-NC-ND 4.0 · Joints 2017; 05(03): 191-194
DOI: 10.1055/s-0037-1605384
Technical Note
Georg Thieme Verlag KG Stuttgart · New York

Successful Treatment of Osgood–Schlatter Disease with Autologous-Conditioned Plasma in Two Patients

Dirk-Jonas Danneberg
1   Department of Orthopaedics and Sports Medicine, Darmstadt, Germany
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
24. August 2017 (online)

   Lizenzen und Reprints

Abstract

Osgood–Schlatter Disease (OSD) is a painful, growth-related overuse condition of the tibial tuberosity, leading to inflammation of the patellar ligament at the tibial tuberosity. It primarily affects young adolescents, athletic population, and usually, resolves with age or skeletal maturity. Therapy is usually conservative, with surgery indicated in a minority of cases. For patients with treatment-resistant or refractory OSD, an alternative is the application of autologous platelet concentrate. Here, we describe two cases in which autologous-conditioned plasma therapy was used to treat OSD, and present the treatment protocol developed in our clinic.

Keywords

Osgood–Schlatter disease - autologous-conditioned plasma - platelet concentrate - patellar ligament - apophysitis

Note

Patient consent has been obtained.


 

  • References

  • 1 Caine D, DiFiori J, Maffulli N. Physeal injuries in children's and youth sports: reasons for concern?. Br J Sports Med 2006; 40 (09) 749-760
    CrossrefPubMedGoogle Scholar
  • 2 de Lucena GL, dos Santos Gomes C, Guerra RO. Prevalence and associated factors of Osgood-Schlatter syndrome in a population-based sample of Brazilian adolescents. Am J Sports Med 2011; 39 (02) 415-420
    CrossrefPubMedGoogle Scholar
  • 3 Gholve PA, Scher DM, Khakharia S, Widmann RF, Green DW. Osgood Schlatter syndrome. Curr Opin Pediatr 2007; 19 (01) 44-50
    CrossrefPubMedGoogle Scholar
  • 4 Gerulis V, Kalesinskas R, Pranckevicius S, Birgeris P. Importance of conservative treatment and physical load restriction to the course of Osgood-Schlatter's disease [in Lithuanian]. Medicina (Kaunas) 2004; 40 (04) 363-369
    PubMedGoogle Scholar
  • 5 Mital MA, Matza RA, Cohen J. The so-called unresolved Osgood-Schlatter lesion: a concept based on fifteen surgically treated lesions. J Bone Joint Surg Am 1980; 62 (05) 732-739
    CrossrefPubMedGoogle Scholar
  • 6 Charousset C, Zaoui A, Bellaiche L, Bouyer B. Are multiple platelet-rich plasma injections useful for treatment of chronic patellar tendinopathy in athletes? a prospective study. Am J Sports Med 2014; 42 (04) 906-911
    CrossrefPubMedGoogle Scholar
  • 7 Kon E, Filardo G, Delcogliano M. , et al. Platelet-rich plasma: new clinical application: a pilot study for treatment of jumper's knee. Injury 2009; 40 (06) 598-603
    CrossrefPubMedGoogle Scholar
  • 8 Zayni R, Thaunat M, Fayard JM. , et al. Platelet-rich plasma as a treatment for chronic patellar tendinopathy: comparison of a single versus two consecutive injections. Muscles Ligaments Tendons J 2015; 5 (02) 92-98
    CrossrefPubMedGoogle Scholar
  • 9 Foster TE, Puskas BL, Mandelbaum BR, Gerhardt MB, Rodeo SA. Platelet-rich plasma: from basic science to clinical applications. Am J Sports Med 2009; 37 (11) 2259-2272
    CrossrefPubMedGoogle Scholar
  • 10 Lebiedziński R, Synder M, Buchcic P, Polguj M, Grzegorzewski A, Sibiński M. A randomized study of autologous conditioned plasma and steroid injections in the treatment of lateral epicondylitis. Int Orthop 2015; 39 (11) 2199-2203
    CrossrefPubMedGoogle Scholar
  • 11 Laudy AB, Bakker EW, Rekers M, Moen MH. Efficacy of platelet-rich plasma injections in osteoarthritis of the knee: a systematic review and meta-analysis. Br J Sports Med 2015; 49 (10) 657-672
    CrossrefPubMedGoogle Scholar
  • 12 Eppley BL, Woodell JE, Higgins J. Platelet quantification and growth factor analysis from platelet-rich plasma: implications for wound healing. Plast Reconstr Surg 2004; 114 (06) 1502-1508
    PubMedGoogle Scholar
  • 13 Andia I, Sánchez M, Maffulli Basic Science N. Molecular and biological aspects of platelet-rich plasma therapies. Oper Tech Orthop 2012; 22: 3-9
    CrossrefPubMedGoogle Scholar
  • 14 Kon E, Filardo G, Di Martino A, Marcacci M. Platelet-rich plasma (PRP) to treat sports injuries: evidence to support its use. Knee Surg Sports Traumatol Arthrosc 2011; 19 (04) 516-527
    CrossrefPubMedGoogle Scholar
  • 15 Boswell SG, Cole BJ, Sundman EA, Karas V, Fortier LA. Platelet-rich plasma: a milieu of bioactive factors. Arthroscopy 2012; 28 (03) 429-439
    CrossrefPubMedGoogle Scholar
  • 16 Cerza F, Carnì S, Carcangiu A. , et al. Comparison between hyaluronic acid and platelet-rich plasma, intra-articular infiltration in the treatment of gonarthrosis. Am J Sports Med 2012; 40 (12) 2822-2827
    CrossrefPubMedGoogle Scholar
  • 17 Carofino B, Chowaniec DM, McCarthy MB. , et al. Corticosteroids and local anesthetics decrease positive effects of platelet-rich plasma: an in vitro study on human tendon cells. Arthroscopy 2012; 28 (05) 711-719
    CrossrefPubMedGoogle Scholar